ClinicalTrials.gg
RecruitingNCT06630962COST-FINUpdated Oct 8, 2024

Evaluating the Impact of Financial Navigation on Financial Catastrophe and Distress for Cancer Care

An interventional study of Financial Navigation Program in Breast Neoplasm, Prostate Neoplasm and Colon Neoplasm, sponsored by Northwestern University. Recruiting at 2 sites in Nigeria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-08.

Sponsored by Northwestern University · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Breast Neoplasms by Northwestern University — 4 open to participants now, 6 under way, 1 of them phase 3. Breast Neoplasms · Northwestern University.

Planned enrollment
4th of 50
200 · median 31
Started
2024
with 2 others
No phase
19 of 64
2 open now
Registered
63rd of 64
by date

Among the 64 studies in Breast Neoplasms by Northwestern University, this one is the 4th largest by planned enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2024, is one of 19 with no phase, and was the 63rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 64 studies in Breast Neoplasms by Northwestern University are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Breast Neoplasms by Northwestern University, or all of them as a file.
02

Study summary

The goal of this study is to investigate the effectiveness of a structured financial navigation program in reducing financial catastrophe and financial distress for cancer patients in Nigeria.

The main study questions being investigated are:

  1. If a financial navigation program can effectively and significantly reduce financial catastrophe and distress for cancer patients in Nigeria?
  2. If a financial navigation program is financially sustainable and cost-effective for cancer centers in Nigeria?

Participants will be required to:

  1. Complete surveys about their demographics, clinical history, and socioeconomic status
  2. Complete questionnaires about their quality of life and psychological wellbeing
  3. Report all costs related to their cancer care

Investigators will compare participants in the financial navigation program and those not in the financial navigation program to identify potential differences in catastrophic health expenditure and financial distress.

Read the detailed description

Over 100,000 individuals are diagnosed with cancer annually in Nigeria, the highest burden out of all countries in sub-Saharan Africa (SSA). Treatment options are limited and often delayed due to lack of insurance coverage and high out-of-pocket costs, which is devastating for Nigeria's 83 million living in poverty (40% of the population). Importantly, it is estimated that 77-94% of cancer patients in SSA face financial catastrophe (FC) where health expenses exceed 25% of household expenditure, 40% of non-subsistence expenditures, or 10% of household income.

While Nigeria has recently planned to invest 300 billion USD in the National Cancer Control Plan, a comprehensive initiative to centralize and strengthen multidisciplinary cancer care, high-quality research on innovative methods to eliminate cost barriers and make treatment affordable is needed.

In the United States, structured financial navigation programs (FNP) have been successful in helping patients finance their cancer care, and save costs, and have been associated with reduced levels of financial distress. However, there is paucity of data high-quality on the effectiveness of an FNP for cancer care in SSA.

The proposed study will investigate the effectiveness of an FNP in reducing financial catastrophe and distress for cancer patients in Nigeria. The FNP will hire financial navigators (FNs) at the cancer centers to educate patients on financial literacy, enroll patients in insurance, and find alternative funding sources, such as charitable solutions. The randomized control trial will enroll 200 newly diagnosed breast, colorectal, or prostate cancer patients at two cancer centers in Lagos, Nigeria, and investigate the impact of the FNP on:

  1. The incidence of financial catastrophe
  2. Financial distress
  3. Budget and financial sustainability analysis of the FNP -- by conducting a cost-effectiveness analysis by comparing the program's cost to the benefits in terms of funding secured and number of participants enrolled in insurance.

This study -- the first of its kind in SSA -- will inform the potential for FNPs to reduce the financial burden of cancer treatment in resource-constrained settings. If effective, programs like this would serve as an invaluable resource to increase access to care and in turn improve cancer outcomes in the region.

In light of Nigerian government's recently renewed interest in improving access to cancer care, findings from this study will be crucial in health policy reform. Further, this study's findings will inform and influence cancer care in SSA, and will prompt effectiveness in other similar contexts.

Finally, if found to be effective, data from this investigation will lay the foundation to support an R01-level study to comprehensively evaluate the implementation and adoption of FNPs in Nigeria and other parts of SSA.

03

Conditions studied

  • Breast Neoplasm
  • Prostate Neoplasm
  • Colon Neoplasm
  • Rectal Neoplasm

Keywords

  • Financial Navigation
  • Financing Cancer Care
  • Nigeria
  • Breast Neoplasm
  • Prostate Neoplasm
  • Colon Neoplasm
  • Rectal Neoplasm
  • Health Insurance
  • Randomized Control Trial
  • Healthcare Cost
  • Health Expenditure
  • Financial Risk Sharing
  • Universal Health Insurance
  • National Health Insurance Scheme
  • Catastrophic Health Spending
  • Financial Distress
  • Sub-Saharan Africa
  • Health Plan Implementation
  • Global Health
  • Healthcare Economics and Organizations
  • Clinical Oncology
  • Cancer Care Facilities
  • Surgical Oncology
  • Global Burden of Disease
  • Social Determinants of Health
  • Health Impact Assessment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years and older
  • Recently diagnosed with breast, colorectal or prostate cancer within 6 weeks of presentation at the study site
  • Have not received definitive chemotherapy, radiotherapy, or undergone major surgery (diagnostic or temporary interventions, such as excisional or temporary colostomy may still enroll)
  • Candidate for definitive cancer treatment

Exclusion criteria

Exclusion Criteria:

  • Unable to provide consent
  • Has initiated definitive cancer treatment at the study site or elsewhere in the past
  • Only receiving best supportive care
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Financial Navigation Arm

    A financial navigator will educate these participants on financial literacy, insurance plans and payment options available through charities and financial assistance programs. In addition to providing financial counseling, the financial navigator will verify participant insurance documents, maintain records of financial agreements, and coordinate payments with insurance companies.

    Other: Financial Navigation Program

  • No intervention
    Routine Care Arm

    Participants will not have access to the services of the financial navigator. Financial counseling and assistance will be limited to what is routinely provided by the cancer center.

Interventions

  • OtherFinancial Navigation Program

    A salaried financial navigator will be hired by the study sites. All responsibilities of the navigator will revolve around the structured financial navigation program. There is currently no research indicating that such a role has been incorporated at cancer centers in sub-Saharan Africa. Through this program, the financial navigator will educate participants on financial literacy, insurance plans and payment options available through charities and financial assistance programs. In addition to providing financial counseling, the financial navigator will verify participant insurance documents, maintain records of financial agreements, and coordinate payments with insurance companies.

06

What researchers measure

Primary outcomes

  1. Incidence of financial catastrophe (FC)

    To compare the incidence of FC between participants in the financial navigation program (FNP) and control arms. FC is defined as treatment-related costs that exceed 10% of household income (HHI), 25% of total household expenditure (HHE), or 40% of non-essential household spending (HSE). All direct and indirect out-of-pocket (OOP) costs of cancer care will be summed for each participant and represented as a proportion of HHI, HHE, and HSE.

    Time frame: From enrollment to 12 months

  2. Levels of financial distress (FD)

    To compare the levels of FD experienced between participants in the FNP and control arms. Financial Distress (FD) will be measured using the FACIT-COST tool, a validated patient-reported measure with scores ranging from 0-44 (higher scores represent better financial well-being). FACIT-COST scores will be assessed for all participants at 3, 6, and 12 months from enrollment, and mean scores at 6 months will be compared between both study arms.

    Time frame: From enrollment to 3, 6 and 12 months

Secondary outcomes

  1. Rate of cost-related non-adherence

    Exploratory analysis to compare the rates of treatment non-adherence related to treatment costs between the FNP and control arms. Data on adherence and reasons for non-adherence will be collected through structured interviews with participants and their treating medical oncologists 6 months post-enrollment.

    Time frame: From enrollment to 6 months

07

Study locations

2 of 2 sites recruiting
  • Obafemi Awolowo University Teaching Hospitals Complex
    Ile-Ife, Nigeria
    Recruiting
    • Isaiah Oyewole · Contact
    • Funmilola Wuraola · Sub investigator
  • Lakeshore Cancer Center
    Lagos, Nigeria
    Recruiting
    • Bindiya Sadarangani · Contact
    • Chinenye Iwuji · Sub investigator
08

References and documents

Publications

  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PubMed 33538338 ↗
  • The Lancet. GLOBOCAN 2018: counting the toll of cancer. Lancet. 2018 Sep 22;392(10152):985. doi: 10.1016/S0140-6736(18)32252-9. Epub 2018 Sep 20. No abstract available. Erratum In: Lancet. 2018 Oct 6;392(10154):1196. doi: 10.1016/S0140-6736(18)32393-6. PubMed 30264708 ↗
  • Awodutire PO, Kolawole OA, Ilori OR. Data on the survival times of breast cancer patients in a Teaching Hospital, Osogbo. Data Brief. 2020 Aug 1;32:106109. doi: 10.1016/j.dib.2020.106109. eCollection 2020 Oct. PubMed 32817870 ↗
  • Ali-Gombe M, Mustapha MI, Folasire A, Ntekim A, Campbell OB. Pattern of survival of breast cancer patients in a tertiary hospital in South West Nigeria. Ecancermedicalscience. 2021 Feb 25;15:1192. doi: 10.3332/ecancer.2021.1192. eCollection 2021. PubMed 33889201 ↗
  • Gullickson C, Goodman M, Joko-Fru YW, Gnangnon FHR, N'Da G, Woldegeorgis MA, Buziba NG, Karugu C, Manraj SS, Lorenzoni CF, Hansen R, Finesse A, Somdyala NIM, Bukirwa P, Chingonzoh T, Chokunonga E, Liu B, Kantelhardt E, Parkin DM, Jemal A. Colorectal cancer survival in sub-Saharan Africa by age, stage at diagnosis and Human Development Index: A population-based registry study. Int J Cancer. 2021 Oct 15;149(8):1553-1563. doi: 10.1002/ijc.33715. Epub 2021 Jul 21. PubMed 34164808 ↗
  • Saluja S, Alatise OI, Adewale A, Misholy J, Chou J, Gonen M, Weiser M, Kingham TP. A comparison of colorectal cancer in Nigerian and North American patients: is the cancer biology different? Surgery. 2014 Aug;156(2):305-10. doi: 10.1016/j.surg.2014.03.036. Epub 2014 Jun 19. PubMed 24953266 ↗
  • Seraphin TP, Joko-Fru WY, Manraj SS, Chokunonga E, Somdyala NIM, Korir A, N'Da G, Finesse A, Wabinga H, Assefa M, Gnangnon F, Hansen R, Buziba NG, Liu B, Kantelhardt EJ, Parkin DM. Prostate cancer survival in sub-Saharan Africa by age, stage at diagnosis, and human development index: a population-based registry study. Cancer Causes Control. 2021 Sep;32(9):1001-1019. doi: 10.1007/s10552-021-01453-x. Epub 2021 Jul 10. PubMed 34244896 ↗
  • Ekeke O, Amusan O, Eke N. Management of prostate cancer in port harcourt, Nigeria: changing patterns. J West Afr Coll Surg. 2012 Jul;2(3):58-77. PubMed 25452994 ↗
  • Araghi M, Arnold M, Rutherford MJ, Guren MG, Cabasag CJ, Bardot A, Ferlay J, Tervonen H, Shack L, Woods RR, Saint-Jacques N, De P, McClure C, Engholm G, Gavin AT, Morgan E, Walsh PM, Jackson C, Porter G, Moller B, Bucher O, Eden M, O'Connell DL, Bray F, Soerjomataram I. Colon and rectal cancer survival in seven high-income countries 2010-2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project). Gut. 2021 Jan;70(1):114-126. doi: 10.1136/gutjnl-2020-320625. Epub 2020 Jun 1. PubMed 32482683 ↗
  • Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, Bonaventure A, Valkov M, Johnson CJ, Esteve J, Ogunbiyi OJ, Azevedo E Silva G, Chen WQ, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP; CONCORD Working Group. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018 Mar 17;391(10125):1023-1075. doi: 10.1016/S0140-6736(17)33326-3. Epub 2018 Jan 31. PubMed 29395269 ↗
  • Mustapha MI, Ali-Gombe M, Abdullahi A, Adenipekun A, Campbell OB. Financial Burden of Cancer on Patients Treated at a Tertiary Health Facility in South West Nigeria. J West Afr Coll Surg. 2020 Oct-Dec;10(4):23-29. doi: 10.4103/jwas.jwas_4_22. Epub 2022 Jun 8. PubMed 35814963 ↗
  • Sharma A, Alatise OI, Adisa AO, Arowolo OA, Olasehinde O, Famurewa OC, Omisore AD, Komolafe AO, Olaofe O, Katung AI, Ibikunle AD, Egberongbe AA, Olatoke SA, Agodirin SO, Adesiyun AO, Adeyeye A, Ibrahim K, Kolawole OA, Idris OL, Adejumobi MO, Ajayi AI, Olakanmi AO, Constable JC, Seier K, Gonen M, Brennan MF, Kingham TP. Treatment of colorectal cancer in Sub-Saharan Africa: Results from a prospective Nigerian hospital registry. J Surg Oncol. 2020 Feb;121(2):342-349. doi: 10.1002/jso.25768. Epub 2019 Nov 19. PubMed 31742699 ↗
  • Sharma A, Alatise OI, O'Connell K, Ogunleye SG, Aderounmu AA, Samson ML, Wuraola F, Olasehinde O, Kingham TP, Du M. Healthcare utilisation, cancer screening and potential barriers to accessing cancer care in rural South West Nigeria: a cross-sectional study. BMJ Open. 2021 Jul 26;11(7):e040352. doi: 10.1136/bmjopen-2020-040352. PubMed 34312189 ↗
  • Fapohunda A, Fakolade A, Omiye J, Afolaranmi O, Arowojolu O, Oyebamiji T, Nwogu C, Olawaiye A, Mutiu J. Cancer presentation patterns in Lagos, Nigeria: Experience from a private cancer center. J Public Health Afr. 2020 Dec 31;11(2):1138. doi: 10.4081/jphia.2020.1138. eCollection 2020 Dec 31. PubMed 33623651 ↗
  • Knapp GC, Wuraola FO, Olasehinde O, Romanoff A, Kingham PT, Alatise OI. The out-of-pocket cost of breast cancer care at a public tertiary care hospital in Nigeria: an exploratory analysis. Pan Afr Med J. 2022 Apr 5;41:272. doi: 10.11604/pamj.2022.41.272.24610. eCollection 2022. PubMed 35784593 ↗
  • Okoroh J, Sarpong DO, Essoun S, Riviello R, Harris H, Weissman JS. Does insurance protect individuals from catastrophic payments for surgical care? An analysis of Ghana's National Health Insurance Scheme at Korle-Bu teaching Hospital. BMC Health Serv Res. 2020 Jan 17;20(1):45. doi: 10.1186/s12913-020-4887-2. PubMed 31952520 ↗
  • Kasahun GG, Gebretekle GB, Hailemichael Y, Woldemariam AA, Fenta TG. Catastrophic healthcare expenditure and coping strategies among patients attending cancer treatment services in Addis Ababa, Ethiopia. BMC Public Health. 2020 Jun 22;20(1):984. doi: 10.1186/s12889-020-09137-y. PubMed 32571275 ↗
  • Alawode GO, Adewole DA. Assessment of the design and implementation challenges of the National Health Insurance Scheme in Nigeria: a qualitative study among sub-national level actors, healthcare and insurance providers. BMC Public Health. 2021 Jan 11;21(1):124. doi: 10.1186/s12889-020-10133-5. PubMed 33430837 ↗
  • GBD 2019 Universal Health Coverage Collaborators. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1250-1284. doi: 10.1016/S0140-6736(20)30750-9. Epub 2020 Aug 27. PubMed 32861314 ↗
  • Adisa AO, Lawal OO, Adesunkanmi AR. Paradox of wellness and nonadherence among Nigerian women on breast cancer chemotherapy. J Cancer Res Ther. 2008 Jul-Sep;4(3):107-10. doi: 10.4103/0973-1482.42640. PubMed 18923201 ↗
  • Okoronkwo IL, Ejike-Okoye P, Chinweuba AU, Nwaneri AC. Financial barriers to utilization of screening and treatment services for breast cancer: an equity analysis in Nigeria. Niger J Clin Pract. 2015 Mar-Apr;18(2):287-91. doi: 10.4103/1119-3077.151070. PubMed 25666009 ↗
  • ACTION Study Group; Kimman M, Jan S, Yip CH, Thabrany H, Peters SA, Bhoo-Pathy N, Woodward M. Catastrophic health expenditure and 12-month mortality associated with cancer in Southeast Asia: results from a longitudinal study in eight countries. BMC Med. 2015 Aug 18;13:190. doi: 10.1186/s12916-015-0433-1. PubMed 26282128 ↗
  • Sullivan R, Alatise OI, Anderson BO, Audisio R, Autier P, Aggarwal A, Balch C, Brennan MF, Dare A, D'Cruz A, Eggermont AM, Fleming K, Gueye SM, Hagander L, Herrera CA, Holmer H, Ilbawi AM, Jarnheimer A, Ji JF, Kingham TP, Liberman J, Leather AJ, Meara JG, Mukhopadhyay S, Murthy SS, Omar S, Parham GP, Pramesh CS, Riviello R, Rodin D, Santini L, Shrikhande SV, Shrime M, Thomas R, Tsunoda AT, van de Velde C, Veronesi U, Vijaykumar DK, Watters D, Wang S, Wu YL, Zeiton M, Purushotham A. Global cancer surgery: delivering safe, affordable, and timely cancer surgery. Lancet Oncol. 2015 Sep;16(11):1193-224. doi: 10.1016/S1470-2045(15)00223-5. PubMed 26427363 ↗
  • McKenzie F, Zietsman A, Galukande M, Anele A, Adisa C, Cubasch H, Parham G, Anderson BO, Abedi-Ardekani B, Schuz J, Dos Santos Silva I, McCormack V. African Breast Cancer-Disparities in Outcomes (ABC-DO): protocol of a multicountry mobile health prospective study of breast cancer survival in sub-Saharan Africa. BMJ Open. 2016 Aug 23;6(8):e011390. doi: 10.1136/bmjopen-2016-011390. PubMed 27554102 ↗
  • Bell-Brown A, Watabayashi K, Delaney D, Carlos RC, Langer SL, Unger JM, Vaidya RR, Darke AK, Hershman DL, Ramsey SD, Shankaran V. Assessment of financial screening and navigation capabilities at National Cancer Institute community oncology clinics. JNCI Cancer Spectr. 2023 Aug 31;7(5):pkad055. doi: 10.1093/jncics/pkad055. PubMed 37561111 ↗
  • Yezefski T, Steelquist J, Watabayashi K, Sherman D, Shankaran V. Impact of trained oncology financial navigators on patient out-of-pocket spending. Am J Manag Care. 2018 Mar;24(5 Suppl):S74-S79. PubMed 29620814 ↗
  • Edward JS, McLouth LE, Rayens MK, Eisele LP, Davis TS, Hildebrandt G. Coverage and Cost-of-Care Links: Addressing Financial Toxicity Among Patients With Hematologic Cancer and Their Caregivers. JCO Oncol Pract. 2023 May;19(5):e696-e705. doi: 10.1200/OP.22.00665. Epub 2023 Mar 8. PubMed 36888937 ↗
  • Doherty MJ, Thom B, Gany F. Evidence of the Feasibility and Preliminary Efficacy of Oncology Financial Navigation: A Scoping Review. Cancer Epidemiol Biomarkers Prev. 2021 Oct;30(10):1778-1784. doi: 10.1158/1055-9965.EPI-20-1853. Epub 2021 Aug 2. PubMed 34341051 ↗
  • Sadigh G, Gallagher K, Obenchain J, Benson A 3rd, Mitchell E, Sengupta S, Carlos RC. Pilot Feasibility Study of an Oncology Financial Navigation Program in Brain Cancer Patients. J Am Coll Radiol. 2019 Oct;16(10):1420-1424. doi: 10.1016/j.jacr.2019.07.014. No abstract available. PubMed 31585660 ↗
  • Shankaran V, Leahy T, Steelquist J, Watabayashi K, Linden H, Ramsey S, Schwartz N, Kreizenbeck K, Nelson J, Balch A, Singleton E, Gallagher K, Overstreet K. Pilot Feasibility Study of an Oncology Financial Navigation Program. J Oncol Pract. 2018 Feb;14(2):e122-e129. doi: 10.1200/JOP.2017.024927. Epub 2017 Dec 22. PubMed 29272200 ↗
  • Kircher SM, Yarber J, Rutsohn J, Guevara Y, Lyleroehr M, Alphs Jackson H, Walradt J, Desai B, Mulcahy M, Kalyan A, Benson AB, Agulnik M, Mohindra N, DeSouza J, Garcia SF. Piloting a Financial Counseling Intervention for Patients With Cancer Receiving Chemotherapy. J Oncol Pract. 2019 Mar;15(3):e202-e210. doi: 10.1200/JOP.18.00270. Epub 2019 Jan 9. PubMed 30625023 ↗
  • Watabayashi K, Steelquist J, Overstreet KA, Leahy A, Bradshaw E, Gallagher KD, Balch AJ, Lobb R, Lavell L, Linden H, Ramsey SD, Shankaran V. A Pilot Study of a Comprehensive Financial Navigation Program in Patients With Cancer and Caregivers. J Natl Compr Canc Netw. 2020 Oct 1;18(10):1366-1373. doi: 10.6004/jnccn.2020.7581. Print 2020 Oct. PubMed 33022646 ↗
  • Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999 Sep;89(9):1322-7. doi: 10.2105/ajph.89.9.1322. PubMed 10474547 ↗
  • Sadigh G, Coleman D, Lava N, Switchenko J, Vargas D, Duszak R Jr, Carlos RC. Patient-Specific Out-of-Pocket Cost Communication and Remote Financial Navigation in Patients with Multiple Sclerosis: A Randomized Controlled Feasibility Study. Mult Scler Relat Disord. 2022 Jun;62:103797. doi: 10.1016/j.msard.2022.103797. Epub 2022 Apr 10. PubMed 35429820 ↗
  • Sadigh G, Coleman D, Switchenko JM, Hopkins JO, Carlos RC. Treatment out-of-pocket cost communication and remote financial navigation in patients with cancer: a feasibility study. Support Care Cancer. 2022 Oct;30(10):8173-8182. doi: 10.1007/s00520-022-07270-5. Epub 2022 Jul 7. PubMed 35796885 ↗
  • Okoroh J, Essoun S, Seddoh A, Harris H, Weissman JS, Dsane-Selby L, Riviello R. Evaluating the impact of the national health insurance scheme of Ghana on out of pocket expenditures: a systematic review. BMC Health Serv Res. 2018 Jun 7;18(1):426. doi: 10.1186/s12913-018-3249-9. PubMed 29879978 ↗
  • Okoroh JS, Chia V, Oliver EA, Dharmawardene M, Riviello R. Strengthening Health Systems of Developing Countries: Inclusion of Surgery in Universal Health Coverage. World J Surg. 2015 Aug;39(8):1867-74. doi: 10.1007/s00268-015-3031-7. PubMed 25802236 ↗
  • Chakraborty NM, Fry K, Behl R, Longfield K. Simplified Asset Indices to Measure Wealth and Equity in Health Programs: A Reliability and Validity Analysis Using Survey Data From 16 Countries. Glob Health Sci Pract. 2016 Mar 25;4(1):141-54. doi: 10.9745/GHSP-D-15-00384. Print 2016 Mar. PubMed 27016550 ↗
  • de Souza JA, Yap BJ, Wroblewski K, Blinder V, Araujo FS, Hlubocky FJ, Nicholas LH, O'Connor JM, Brockstein B, Ratain MJ, Daugherty CK, Cella D. Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST). Cancer. 2017 Feb 1;123(3):476-484. doi: 10.1002/cncr.30369. Epub 2016 Oct 7. PubMed 27716900 ↗
  • Nwankwo T, Ogunyemi AO, Maduafokwa BA, Isikekpei BC, Alabi AO, Adegboyega BC, Otokpa E. Psychosocial Support and Cost Burden of Cancer Among Patients Attending Tertiary Oncology Clinics in Lagos State, Nigeria. Asian Pac J Cancer Prev. 2023 Jul 1;24(7):2313-2319. doi: 10.31557/APJCP.2023.24.7.2313. PubMed 37505761 ↗
  • Shih W. Problems in dealing with missing data and informative censoring in clinical trials. Curr Control Trials Cardiovasc Med. 2002 Jan 8;3(1):4. doi: 10.1186/1468-6708-3-4. PubMed 11985778 ↗
  • DeSouza CM, Legedza AT, Sankoh AJ. An overview of practical approaches for handling missing data in clinical trials. J Biopharm Stat. 2009 Nov;19(6):1055-73. doi: 10.1080/10543400903242795. PubMed 20183464 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Demographic, socioeconomic, clinical, cost, and patient-reported outcome data will be uploaded and shared for each enrolled participant. All data will be de-identified and dates will be excluded from the dataset.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be shared at study conclusion, once all analyses are complete. The data will be available to the wider research community indefinitely.

Access criteria: Data will be accessible to anyone in the wider research community via the clinicaltrials.gov repository. The data will be identifiable through a unique identification code assigned by clinicaltrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jul 2026, 24 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 24 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2024
First posted
Oct 8, 2024
StartActual
Jul 15, 2024
Primary completionEst.
Jul 2026
CompletionEst.
Sep 2026
Last update
Oct 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06630962
Responsible party
Sponsor
First posted
Oct 8, 2024
Start date
Jul 15, 2024
Primary completion
Jul 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Oct 8, 2024

Study contacts

Juliet Lumati
Contact
juliet.lumati@northwestern.edu
+1 312 926 4230
Kristina Diaz
Contact
kristina.diaz@northwestern.edu
2027253279
Juliet Lumati
principal investigator · Northwestern University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion